Table 1

Baseline characteristics of COPD outpatients with first exacerbation in treatment groups.

Doxycycline
(n=2261)
Reference
(n=4039)
P value
Gender, no. (%)
 Male1085 (48.0)1999 (49.5)0.252
 Female1176 (52.0)2040 (50.5)
Age, years, no. (%)
 Mean age (SD)71.08 (9.6)70.30 (9.4)0.002*
 55–64667 (29.5)1285 (31.8)0.018†
 65–74733 (32.4)1357 (33.6)
 ≥75861 (38.1)1397 (34.6)
Year of index date (%)
 1996–2004893 (39.5)1676 (41.5)0.121
 2005–20151368 (60.5)2363 (58.5)
Prescriber
 GP2147 (95.0)3424 (84.8)<0.001
 Specialist114 (5.0)615 (15.2)
Maintenance medicines, no. (%)
 SABA775 (34.3)1579 (39.1)<0.001
 LABA494 (21.8)847 (21.0)0.414
 SAMA689 (30.5)1216 (30.1)0.761
 LAMA555 (24.5)1020 (25.3)0.534
 SABA/SAMA80 (3.5)173 (4.3)0.149
 LABA/LAMA0 (0)1 (0)0.454
 LABA/ICS1093 (48.3)1846 (45.7)0.044
 Theophylline124 (5.5)159 (3.9)0.004
Comorbidity, no. (%)
 Diabetes mellitus301 (13.3)504 (12.5)0.341
 Disorders of lipid metabolism629 (27.8)1093 (27.1)0.517
 Heart failure363 (16.1)676 (16.7)0.484
 Ischaemic heart disease206 (9.1)336 (8.3)0.282
 Other cardiovascular disorders843 (37.3)1493 (37.0)0.801
 Thyroid disease115 (5.1)192 (4.8)0.556
 Rheumatic arthritis355 (15.7)660 (16.3)0.508
 Osteoporosis117 (5.2)232 (5.7)0.343
 Anxiety392 (17.3)649 (16.1)0.193
 Depression274 (12.1)438 (10.8)0.125
 Dementias9 (0.4)10 (0.2)0.296
  • *Student’s t-test.

  • †Pearson χ2 test;.

  • COPD, chronic obstructive pulmonary disease; GP, general practitioner; ICS, inhaled corticosteroid; LABA, long-acting β agonist; LABA/ICS, long-acting β agonist/inhaled corticosteroid; LABA/LAMA, long-acting β agonist/long-acting muscarinic antagonist combinations; LAMA, long-acting muscarinic antagonist; SABA, short-acting β agonist; SABA/SAMA, short-acting β agonist/short-acting muscarinic antagonist combinations; SAMA, short-acting muscarinic antagonist.